Comparing TULSA to robotic radical prostatectomy (RP), analyst Rahul Sarugaser, Ph.D., said, “We find that the economics for both hospitals and physicians are about equivalent. So, with this even playing field, we expect TULSA’s adoption to be driven based on its favorable safety profile relative to RP.”
Dr. Sarugaser added that, supported by head-to-head TULSA versus RP data from the CAPTAIN trial in mid-2025, TULSA should begin establishing itself as standard-of-care treatment for all stages of localized prostate disease (i.e. from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and BPH; to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer). “As such, we reiterate our Strong Buy rating.”
Market Data 
Markets 
AI
